Mass Torts & Class Actions
Ozempic, Wegovy & Mounjaro
Litigation over serious injuries alleged from GLP-1 diabetes and weight-loss drugs.
Overview
Understanding Ozempic, Wegovy & Mounjaro cases
GLP-1 medications — including Ozempic, Wegovy, and Mounjaro — became some of the most prescribed drugs in America in just a few years. Lawsuits allege that manufacturers failed to adequately warn about serious risks, including gastroparesis (stomach paralysis) and NAION, an eye condition that can cause sudden and permanent vision loss.
Gastroparesis can mean persistent vomiting, malnutrition, hospitalization, and long-term digestive damage. NAION can take part or all of a person’s sight with little warning. The litigation contends patients deserved clear warnings about both.
If you used these medications for at least several months and then received treatment for gastroparesis, NAION, or similar serious injuries, we can review your situation and explain your options honestly.
These cases generally involve
Where the case is built
- Use of Ozempic, Wegovy, Mounjaro, or similar GLP-1 drugs for at least three months
- Treatment for gastroparesis (stomach paralysis)
- Diagnosis of NAION or other serious vision injury
- Claims that warnings did not match the known risks
The information on this page is general and not legal advice. Every situation is different. Contact us to discuss the specifics of your case.
Related
Other mass torts cases we handle
Free, confidential consultation
Talk to a lawyer who will listen
Tell us what happened. We will review your situation and give you an honest read on your options, with no obligation.